M&R Capital Management Inc. lowered its stake in shares of Medtronic plc (NYSE:MDT – Get Rating) by 3.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,838 shares of the medical technology company’s stock after selling 226 shares during the quarter. M&R Capital Management Inc.’s holdings in Medtronic were worth $454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MDT. BlackRock Inc. raised its stake in Medtronic by 5.1% in the third quarter. BlackRock Inc. now owns 115,998,561 shares of the medical technology company’s stock valued at $9,366,883,000 after buying an additional 5,620,477 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Medtronic by 33.1% in the third quarter. Bank of New York Mellon Corp now owns 19,374,686 shares of the medical technology company’s stock valued at $1,564,508,000 after buying an additional 4,816,172 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in Medtronic by 322.3% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,554,073 shares of the medical technology company’s stock valued at $286,991,000 after buying an additional 2,712,530 shares during the last quarter. Great West Life Assurance Co. Can purchased a new stake in Medtronic in the third quarter valued at about $198,877,000. Finally, Renaissance Technologies LLC purchased a new stake in Medtronic in the second quarter valued at about $212,918,000. 80.37% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Medtronic
In other news, major shareholder Plc Medtronic purchased 6,835 shares of the stock in a transaction dated Monday, January 30th. The shares were purchased at an average cost of $9.28 per share, with a total value of $63,428.80. Following the completion of the purchase, the insider now directly owns 4,999,423 shares of the company’s stock, valued at approximately $46,394,645.44. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.29% of the company’s stock.
Analysts Set New Price Targets
Medtronic Price Performance
MDT traded down $0.98 during trading on Friday, hitting $78.29. The company’s stock had a trading volume of 8,838,609 shares, compared to its average volume of 6,420,709. The company has a current ratio of 1.76, a quick ratio of 1.39 and a debt-to-equity ratio of 0.43. Medtronic plc has a twelve month low of $75.76 and a twelve month high of $114.31. The business’s fifty day simple moving average is $82.06 and its 200 day simple moving average is $82.25. The firm has a market capitalization of $104.16 billion, a price-to-earnings ratio of 25.75, a P/E/G ratio of 2.36 and a beta of 0.71.
Medtronic (NYSE:MDT – Get Rating) last issued its quarterly earnings results on Tuesday, February 21st. The medical technology company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.03. The firm had revenue of $7.70 billion for the quarter, compared to analyst estimates of $7.53 billion. Medtronic had a return on equity of 13.37% and a net margin of 13.20%. The business’s revenue was down .8% on a year-over-year basis. During the same period in the previous year, the company posted $1.37 earnings per share. On average, equities research analysts forecast that Medtronic plc will post 5.28 EPS for the current fiscal year.
Medtronic Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, April 14th. Stockholders of record on Friday, March 24th will be paid a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.47%. The ex-dividend date of this dividend is Thursday, March 23rd. Medtronic’s dividend payout ratio is presently 89.47%.
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.
- Get a free copy of the StockNews.com research report on Medtronic (MDT)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Get Rating).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.